• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Shorter overall survival among patients with monoclonal gammopathy of undetermined significance

byDayton McMillan
January 23, 2018
in Chronic Disease, Nephrology, Oncology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS) and followed for multiple decades showed shorter overall survival rates compared to matched controls.

2. Risk of progression to multiple myeloma or another blood cell disorder was associated with identified adverse risk factors.

Evidence Rating: 1 (Excellent)

Study Rundown: MGUS is a relatively common condition occurring in over 3% of persons age 50 or older which predisposes patients to increased risk of malignant plasma cell transformation. Prior studies have followed patients for less than 10 years, providing information regarding risks of malignant transformation. Data from longer follow-up is desired as the condition can be slowly progressive and have subtypes with different manifestations. This study follows a large group of MGUS patients for a median of 34.1 years. The primary endpoint of progression to multiple myeloma or plasma-cell or lymphoid disorders was increased compared to a control population, with risk of progression increasing as time with the condition increased. Adverse risk factors were identified which were associated with increased risk of progression. The IgM subtype of MGUS displayed an increased risk of progression compared to the non-IgM MGUS subtype. Overall survival was decreased in MGUS patients compared to matched controls.

This study provides improved natural history data on the progression of MGUS. Its strengths include large size and validation of adverse risk factors associated with disease progression, and a notable feature is the patient population was highly homogeneous.

Click to read the study, published in NEJM

Relevant Reading: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies

RELATED REPORTS

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide

In-Depth [prospective cohort]: This prospective cohort study followed 1384 patients for a total of 14 130 person-years from Minnesota diagnosed with MGUS at the Mayo Clinic between 1960 and 1994. Diagnostic criteria included a serum M protein level of 3 grams per deciliter or less and 10% or fewer plasma cells in bone marrow. Patients with light-chain MGUS were excluded. Follow-up consisted of Mayo medical records review and death certificate analysis. The primary endpoint was rate of progression to multiple myeloma or plasma-cell or lymphoid disorders in IgM (n = 210) and non-IgM (n = 1129) subtypes. Analysis of various prognostic factors associated with risk of progression was performed, as well as assessment of overall survival.

During the median of 34.1 years of follow-up 94% of patients passed away. Disease progression occurred in 11% of patients, at a risk 6.5 times higher than a matched cohort (95% confidence interval [CI], 5.5 to 7.7). Risk of disease progression was higher in the IgM (relative risk [RR], 10.8; 95% CI, 7.5 to 15.0) compared to non-IgM subtype (RR, 5.7; 95% CI, 4.7 to 6.9). Risk of progression was 10% at 10 years, 18% at 20 years, 28% at 30 years, 36% at 35 years, and 36% at 40 years. Initial concentration of serum M protein and serum free light-chain ratio were adverse risk factors associated with risk of progression. At 40 years, risk of death related to plasma- cell disorders was 11%. Compared to a matched cohort MGUS patients had a shorter median survival time (8.1 vs 12.4 years, p < 0.001).

Image: CC/Wiki

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: mgusmultiple myeloma
Previous Post

Shorter pediatric tuberculosis treatment linked to higher completion rates

Next Post

First trimester exposure to antithyroid drugs associated with increased risk of birth defects

RelatedReports

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma
StudyGraphics

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

February 3, 2022
#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide
StudyGraphics

#VisualAbstract: Melflufen plus dexamethasone showed superior progression-free survival over standard of care in multiple myeloma refractory to lenalidomide

January 27, 2022
#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma
StudyGraphics

#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma

December 18, 2021
Next Post
Late gestation antidepressant use linked to postpartum hemorrhage

First trimester exposure to antithyroid drugs associated with increased risk of birth defects

Past marijuana exposure linked to impaired verbal memory

Insufficient evidence to determine if marijuana use can affect cardiovascular risk

Physician visual assessment of coronary stenosis severity overestimates quantitative coronary angiography

Physician visual assessment of coronary stenosis severity overestimates quantitative coronary angiography

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.